公司作为国产血液净化设备的龙头企业，依托技术领先优势和强大的品牌效应，产品市场占有率持续提 升，推动了血液净化设备销售收入的稳步增长；报告期内公司自产的血液净化耗材销售收入大幅提升； 同时随着产销量的提升，自产耗材单位固定成本进一步下降，毛利率提升，公司总体盈利能力进一步加 强。 格隆汇2月27日丨山外山(688410.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入8.07亿 元，较上年同期增加42.23%；实现归属于母公司所有者的净利润1.43亿元，较上年同期增加101.89%； 实现归属于母公司所有者的扣除非经常性损益的净利润1.38亿元，较上年同期增加141.34%。 ...

Core Viewpoint - The company, Shanwaishan, has shown significant growth in its blood purification equipment and consumables sales, indicating a strong market position and potential for future expansion in both domestic and international markets. Group 1: Financial Performance - In Q3 2025, the revenue from blood purification equipment reached 393.08 million yuan, representing a year-on-year growth of 39.70% [7] - During the same period, revenue from blood purification consumables was 136.96 million yuan, with a year-on-year increase of 46.47% [7] - The total market capitalization of Shanwaishan is currently 5.456 billion yuan, ranking 68th in the medical device sector [1] Group 2: Market Position and Strategy - The company holds a leading position in the domestic market, with a market share of 21.44% for blood dialysis machines, making it the top domestic brand [3] - The market share for continuous blood purification equipment is 20.77%, also leading the industry [3] - The company is focusing on technological innovation and market demand to drive growth, aiming to expand both domestically and internationally [3] Group 3: International Expansion - The company has made strides in its international strategy, achieving breakthroughs in emerging markets such as Latin America and Africa, with 22 new overseas device registrations [4] - In Q3 2025, revenue from international markets reached 131.92 million yuan, reflecting a year-on-year growth of 43.04% [4] Group 4: Policy and Market Opportunities - The National Development and Reform Commission has proposed policies to enhance the efficiency of equipment update loans, which the company is actively following to explore new opportunities [2] - The company is closely monitoring the price trends and rhythm of centralized procurement for consumables, indicating a proactive approach to market changes [3] Group 5: Future Plans - The company is progressing with its fundraising projects and will continue to monitor market dynamics to ensure successful implementation [5] - Future stock incentive plans will be evaluated based on operational performance, with timely disclosures as necessary [6]

Core Viewpoint - The company, Shanwaishan, expects to achieve a net profit attributable to shareholders of 140 million to 159 million yuan in 2025, representing a year-on-year increase of 98% to 125% [1] - The net profit after deducting non-recurring gains and losses is projected to be 134 million to 154 million yuan, reflecting a year-on-year increase of 135% to 170% [1] Summary by Categories Financial Performance - The anticipated increase in net profit is primarily driven by the company's position as a leading domestic manufacturer of blood purification equipment, leveraging technological advantages and brand effects to boost sales revenue [1] - Significant growth in sales revenue from self-produced blood purification consumables has contributed to the overall financial performance [1] - The increase in production and sales volume has led to a decrease in fixed costs per unit for self-produced consumables, resulting in improved gross margins and overall profitability [1]

Core Viewpoint - The company expects a significant increase in net profit for 2025, with projections indicating a growth of 98.00% to 125.00% year-on-year, driven by its leading position in the domestic blood purification equipment market and enhanced sales of self-produced consumables [1] Group 1: Financial Projections - The projected net profit attributable to shareholders for 2025 is estimated to be between 140 million to 159 million yuan [1] - The projected net profit excluding non-recurring gains and losses is expected to be between 134 million to 154 million yuan, reflecting a year-on-year increase of 135.00% to 170.00% [1] Group 2: Business Drivers - The company's leading position in the blood purification equipment sector, supported by technological advantages and strong brand effects, has led to an increase in market share and steady growth in sales revenue [1] - There has been a significant increase in sales revenue from self-produced blood purification consumables during the reporting period [1] - The rise in production and sales volume has resulted in a decrease in fixed costs per unit for self-produced consumables, leading to an improvement in gross profit margin and overall profitability [1]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of the parent company between 140 million to 159 million yuan in 2025, representing an increase of 69.4686 million to 88.6079 million yuan compared to the previous year, which is a year-on-year increase of 98% to 125% [1] Financial Performance - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between 134 million to 154 million yuan, with an increase of 77.1902 million to 97.2024 million yuan compared to the previous year, indicating a year-on-year growth of 135% to 170% [1] Market Position - The company is a leading domestic player in blood purification equipment, leveraging its technological advantages and strong brand effect to continuously increase its market share [1] - The sales revenue of the company's self-produced blood purification consumables has significantly increased during the reporting period [1]

归属于母公司所有者的扣除非经常性损益的净利润为1.34亿元到1.54亿元，与上年同期(法定披露数据) 相比，将增加7719.02万元到9720.24万元，同比增加135%到170%。 本期业绩变化的主要原因：(一)公司作为国产血液净化设备的龙头企业，依托技术领先优势和强大的品 牌效应，产品市场占有率持续提升，推动了血液净化设备销售收入的稳步增长；(二)报告期内公司自产 的血液净化耗材销售收入大幅提升；(三)随着产销量的提升，自产耗材单位固定成本进一步下降，毛利 率提升，公司总体盈利能力进一步加强。 格隆汇1月30日丨山外山(688410.SH)公布，经公司财务部门初步测算，预计2025年年度实现归属于母公 司所有者的净利润为1.40亿元到1.59亿元，与上年同期(法定披露数据)相比，将增加6946.86万元到 8860.79万元，同比增加98%到125%。 ...

Core Viewpoint - Tianyi Medical, a leading manufacturer of blood purification consumables in China, is expected to achieve rapid performance growth driven by the increasing number of ESRD patients, policy benefits, and expansion into overseas markets [1] Group 1: Company Strategy - The company has strategically acquired to complete the CRRT (Continuous Renal Replacement Therapy) full industry chain product matrix, establishing a complete ecological closed loop of "equipment + consumables + services" [1] - Tianyi Medical has formed three main business pillars: blood dialysis consumables, CRRT, and ward care, supported by a clear strategic layout [1] Group 2: Market Potential - The number of ESRD patients is continuously increasing, and the improvement in treatment rates is driving the long-term stable expansion of the blood dialysis market, which is expected to reach 51.515 billion yuan by 2030 [1] - The company is enhancing its competitive advantage through a combination of "internal growth + external expansion" strategies [1]

Group 1 - The core viewpoint of the news is that the stock price of Chongqing Shanwaishan Blood Purification Technology Co., Ltd. has shown fluctuations, with a recent decline of 2.01% and a current trading price of 15.61 yuan per share, while the company has experienced a year-to-date stock price increase of 4.28% [1][2] - As of October 31, 2025, the company reported a revenue of 584 million yuan, representing a year-on-year growth of 39.79%, and a net profit attributable to shareholders of 104 million yuan, reflecting a year-on-year increase of 68.68% [2] - The company specializes in the research, production, and sales of blood purification equipment, with its main business revenue composition being 66.12% from blood purification equipment, 23.89% from blood purification consumables, 8.31% from medical services, and 1.68% from other sources [2] Group 2 - The company has distributed a total of 104 million yuan in dividends since its A-share listing [3] - As of September 30, 2025, the top ten circulating shareholders include new shareholder Penghua Medical Technology Stock A, holding 5.182 million shares, and BoShi Medical Care Mixed A, holding 3.257 million shares, with the latter's shareholding remaining unchanged from the previous period [3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [13]. Core Insights - The company, 山外山, holds a leading market share in blood dialysis equipment, with a November 2025 market share of 18.75%, surpassing competitors like 费森尤斯 and 贝朗 [3]. - The company has demonstrated robust revenue growth, with a 39.79% increase in revenue to 584 million yuan and a 68.68% increase in net profit to 104 million yuan for the first three quarters of 2025 [4]. - The company is expected to see a significant increase in the contribution of consumables to its overall performance, driven by its leading position in the blood purification equipment market and a focus on enhancing consumable sales [5]. - Revenue projections for 2025-2027 are estimated at 760 million yuan, 950 million yuan, and 1.2 billion yuan, with corresponding net profits of 151 million yuan, 191 million yuan, and 238 million yuan, reflecting a strong growth trajectory [6]. Company Overview - The latest closing price of the company's stock is 14.97 yuan, with a total market capitalization of 4.8 billion yuan [2]. - The company has a total share capital of 320 million shares, with a price-to-earnings ratio of 67.52 [2]. - The company’s largest shareholder is 高光勇 [2].

12月31日，山外山跌0.80%，成交额4207.31万元。两融数据显示，当日山外山获融资买入额620.50万 元，融资偿还715.94万元，融资净买入-95.44万元。截至12月31日，山外山融资融券余额合计9517.01万 元。 融资方面，山外山当日融资买入620.50万元。当前融资余额9486.18万元，占流通市值的1.98%，融资余 额超过近一年60%分位水平，处于较高位。 机构持仓方面，截止2025年9月30日，山外山十大流通股东中，鹏华医药科技股票A（001230）位居第 四大流通股东，持股518.20万股，为新进股东。博时医疗保健混合A（050026）位居第六大流通股东， 持股325.70万股，持股数量较上期不变。 责任编辑：小浪快报 资料显示，重庆山外山血液净化技术股份有限公司位于重庆市两江新区慈济路1号，成立日期2001年3月 26日，上市日期2022年12月26日，公司主营业务涉及血液净化设备的研发、生产和销售。主营业务收入 构成为：血液净化设备66.12%，血液净化耗材23.89%，医疗服务8.31%，其他1.68%。 截至10月31日，山外山股东户数1.12万，较上期增加8.86%；人 ...